前列腺癌中survivin蛋白的表达

目的检测survivin蛋白在前列腺癌组织中的表达,并分析其与病理分级、临床分期的关系。方法采用免疫组织化学链霉菌抗生物素蛋白-过氧化物酶连结法（S-P法）检测45例前列腺癌、50例前列腺增生组织中survivin蛋白的表达。结果Survivin蛋白在前列腺癌组织中表达率为82．2％（37／45）,其表达率在Gleason评分高分组中明显高于低分组（P〈0．01）,表达强度与Gleason评分呈强正相关,而在不同临床分期中表达率无显著性差异。结论Survivin在前列腺癌组织中的表达与survivin前列腺癌恶性程度密切相关,survivin可能在前列腺癌的进展中起重要作用。     

IMPDH2蛋白与前列腺癌临床相关性分析

【摘要】〓目的〓研究IMPDH2在良性前列腺增生和前列腺癌中的表达,并分析其表达水平与临床病理特征的关系。方法〓收集临床手术切除的前列腺癌组织和前列腺增生,或者穿刺活检组织,所有组织均由病理学确诊。排除已做手术去势的前列腺组织。通过Western Blot检测IMPDH2在前列腺癌、前列腺增生组织中IMPDH2蛋白的表达情况|免疫组化检测前列腺癌、前列腺增生标本中IMPDH2的表达。分析IMPDH2基因的表达水平与临床病理特征的关系。结果〓前列腺癌患者组织中IMPDH2蛋白表达显著上调,IMPDH2蛋白表达上调与肿瘤临床分期、Gleason评分、转移相关。结论 IMPDH2在前列腺癌组织中表达上调,前列腺组织中检测IMPDH2可能有助于判断前列腺癌分化程度并评估预后。     

应用组织芯片研究HRG-1基因在前列腺癌和前列腺增生组织中的表达

目的 观察HRG-1基因在前列腺增生和前列腺癌组织的表达,探讨HRG-1作为肿瘤标志物的可能性.方法 应用原位杂交法,检测含有前列腺癌组织（83例）和前列腺增生组织（95例）的组织芯片上HRG-1 mRNA的表达.结果 前列腺腺癌标本中有57例为HRG-1阳性表达,而且大部分为强阳性,阳性率为68.68% 前列腺增生组织中12例表达阳性,阳性率仅为12.63%.HRG-1 mRNA在前列腺癌组织和前列腺增生组织中的表达具有显著差异（P〈0.01）.而在癌组织与癌旁组织的比较中,55例癌旁及正常前列腺组织均为阴性表达,HRG-1 mRNA在癌组织的表达明显高于癌旁及正常组织（P〈0.01）.结论 HRG-1在前列腺癌组织表达水平的特异性升高,提示HRG-1基因有可能作为一种新的肿瘤标志物用于前列腺肿瘤的诊断.     

组织芯片检测前列腺癌中BRG1表达的研究

目的:探讨前列腺癌组织中BRG1基因的表达情况及临床病理意义。方法:运用组织芯片技术、免疫组化EnV ision法检测37例前列腺癌[其中9例中分化腺癌(G leason评分5~7分),28例低分化腺癌(G leason评分8~10分)]、13例前列腺上皮内瘤、14例良性前列腺增生组织中BRG1的表达和分布情况。结果:BRG1在前列腺癌、前列腺上皮内瘤和良性前列腺增生组织中阳性表达率分别为81.08%(30/37)、38.46%(5/13)、14.28%(2/14)。就BRG1阳性表达率而言,前列腺癌组织与前列腺上皮内瘤、前列腺增生组织比较差异均有显著性(P<0.05),前列腺上皮内瘤与前列腺增生组织比较、中分化腺癌与低分化腺癌比较差异均无显著性(P>0.05)。结论:BRG1蛋白在前列腺癌中高表达,对前列腺癌的发生、发展可能起重要作用。组织芯片技术具有高信息量、简捷、快速、高效、成本低、重复性好等优点,在病理学领域中具有重要的实际意义和广阔的应用前景。     

前列腺癌组织中PSA、Ki-67的表达及其临床意义

目的:探讨前列腺特异性抗原(PSA)、Ki-67在前列腺癌组织中的表达与Gleason评分的相关性。方法:采用免疫组化SP法检测43例前列腺癌患者术后石蜡包埋组织中PSA、Ki-67的表达,并根据苏木精-伊红(HE)切片进行Gleason评分。同时,对患者的术前血总前列腺特异性抗原(tPSA)值和对应HE切片中的组织PSA进行比较。结果:在前列腺癌组织中PSA阳性率为93.0%(40/43),其表达量与Gleason评分呈负相关(r=-0.612,P=0.000)。Ki-67阳性表达率为90.7%(39/43),其表达与Gleason评分呈正相关(r=0.696,P=0.000)。PSA与Ki-67在前列腺癌组织中的表达呈无相关性(r=-0.163,P=0.296)。在术前取患者外周血tPSA与癌组织的PSA相比也呈明显的正相关性(r=0.814,P=0.000)。结论:Gleason评分越高,PSA表达越弱,Ki-67表达越强,前列腺癌组织分化程度越差,预后越差。明确前列腺癌Gleason分级,及检测PSA和Ki-67的表达有利于对患者的预后进行评估。     

Ets-1在前列腺癌组织中的表达及其临床意义

目的 探讨原癌基因Ets-1在前列腺组织中的表达及其与前列腺癌组织学分级的关系.方法 利用免疫组化法检测Ets-1在4例正常前列腺组织,12例良性前列腺增生组织和53例前列腺癌组织中的表达.结果 Ets-1蛋白的阳性表达在前列腺癌细胞的胞浆及胞核内均可见,79%的前列腺癌组织中Ets-1呈阳性表达,而在良性前列腺组织细胞中无表达或仅有微弱表达,差异有显著性意义(P<0.05).在前列腺癌组织中,Gleason评分高危组Ets-1阳性表达率明显高于Gleason中危组和低危组(P<0.05).结论 与良性前列腺组织对照相比,Ets-1有肿瘤特异性,其表达与前列腺癌的组织学分级相关,可作为前列腺癌病变程度及临床预后判断的一个分子标志.     

穿刺前列腺癌Gleason评分与血清PSA的相关性分析

目的:探讨穿刺前列腺癌Gleason评分与血清PSA水平的相关性。方法:收集我院2011年5月~2014年6月经前列腺穿刺确诊为前列腺癌且临床资料完整的患者标本81例,对其穿刺组织的Gleason评分与血清PSA水平进行Spearman等级相关性分析。结果:前列腺癌组织Gleason评分与患者血清PSA水平呈正相关(r=0.347,P0.01),PSA值越高,Gleason评分越高。结论:前列腺癌患者血清PSA水平与Gleason评分相关。     

转谷氨酰胺酶4在前列腺癌进展及预后中的作用

转谷氨酰胺酶4（TGM4）在前列腺癌组织和正常组织中差异表达，且与前列腺癌细胞的多种生物学特性相关，如前列腺癌细胞间质化，细胞侵袭性和细胞基质粘附等。本研究主要探索TGM4表达水平与前列腺癌病理特征及前列腺癌生化复发之间的关系。取160名接受前列腺癌根治术患者的石蜡标本构建组织芯片，进而利用组织芯片行TGM4免疫组织化学染色；TGM4的表达情况采用染色范围与染色强度相结合的方式来评价。通过查阅病历获得患者的临床及病理信息；随访信息通过查阅病历、调用我院前列腺癌随访数据库和电话随访等多种方式获得。进而，我们比较了TGM4在癌和癌旁组织中的表达差异情况，及TGM4不同表达水平与前列腺癌病理特征和生化复发之间的关系。同癌旁组织相比，TGM4在前列腺癌组织中明显高表达（P〈0．001），并且其表达水平与Gleason评分（P〈0．001）和PSA水平（P=0．005）呈明显正相关。单变量分析提示TGM4高表达是前列腺癌生化复发的高危因素（P=0．042），但多变量分析并不支持TGM4高表达是前列腺癌生化复发的高危因素（P=0．139）。TGM4在前列腺癌中高表达，其表达水平与Gleason评分和PSA水平呈正相关，TGM4高表达可能作为前列腺癌生化复发的潜在预测因子。     

前列腺癌患者血清PSA、AR表达、Gleason评分和临床分期的相关性研究

目的 探讨前列腺癌患者血清前列腺特异抗原（PSA）、雄激素受体（AR）表达、Gleason评分和临床分期之间的相关性。方法回顾性分析我院55例前列腺癌患者的临床、病理和免疫组化资料。结果TPSA、FPSA值与Gleason评分、临床分期呈正相关,TPSA、FPSA、AR表达强度以及Gleason评分均与临床分期呈正相关（相关系数分别为：0．419,0．385,0．376,0．514）,其中G1eason评分与临床分期的相关性最高。随着TPSA值的升高,对晚期Pca的判断价值明显增大．以TPSA≥30ng／ml为标准判断晚期Pca的准确性较高。结论TPSA、FPSA值、AR表达强度以及Gleason评分值与临床分期有正相关关系,它们可以作为进行临床分期时需综合考虑的因素：TPSA≥30ng／ml可以作为判断晚期Pca有价值的标准。     

转甲状腺素蛋白在前列腺癌组织中的表达以及与分级分期的关系

目的 探讨转甲状腺素蛋白(TTR)在正常前列腺(NP),良性前列腺增生(BPH)以及前列腺癌组织(Pca)中的表达,以及其表达与Pca分期分级的关系.方法 收集我院10例NP、10例BPH以及52例Pca石蜡标本切片,经常规处理后,行TTR免疫组织化学研究.结果 TTR在81%(42/52例)Pca表达强阳性,而NP和BPH无表达强阳性(P<0.05);Gleason评分8～10分Pca94%(16/17例)TTR表达强阳性,Gleason评分2～4分Pca只有50%(5/10例)TTR表达强阳性(P<0.05);TTR在全部8例D期Pca表达强阳性,A期和B期只有33%(2/6例)和79%(19/24)表达强阳性(P<0.05).结论 TTR可能与Pca的发生有关,其在Pca中的表达与Pca分级及分期有关,有可能作为Pca预后的风险因子.     

前列腺癌组织中酪氨酸硫酸化转移酶1(TPST1)的表达水平及临床意义

目的分析酪氨酸硫酸化转移酶1(TPST1)在前列腺癌(PCa)组织中的表达情况,并探讨其与前列腺癌患者临床病理特征和预后的关系。方法在肿瘤基因组图谱(TCGA)数据库收集499例前列腺癌患者,分析TPST1 mRNA与PCa患者临床病理特征及预后的关系;采用免疫组织化学SP法检测前列腺组织芯片(TMA)中TPST1蛋白的表达,并分析其与PCa患者临床病理特征的关系。结果 TCGA数据库结果显示TPST1表达量与年龄具有显著相关性(P<0.05),与血清PSA、Gleason评分、临床T分期、淋巴结转移和远处转移相关性没有统计学意义(P>0.05);免疫组化结果显示,PCa癌组织中TPST1蛋白的高表达率为78.0%(39/50),明显高于非前列腺癌组织的46.67%(14/30),差异有统计学意义(P<0.05);TPST1的TMA分析结果显示,TPST1蛋白表达量与年龄、肿瘤分级、Gleason评分、临床T分期、淋巴结转移以及远处转移相关性没有统计学意义(P>0.05);TCGA数据库样本的Kaplan-Meier生存分析结果显示TPST1 mRNA高表达组的无生化复发生存情况和无病生存情况差于低表达组,差异有统计学意义(P<0.05);COX单因素和多因素分析结果显示,TPST1不是影响PCa患者生存预后的独立危险因素。结论 TPST1在PCa癌组织中呈高表达,TPST1高表达提示预后差,但其与PCa患者临床分期、淋巴结转移无明显相关性,不是影响PCa患者生存预后的独立危险因素。     

Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer

Aim

To assess the predictive value of TGP on biochemical recurrence (BCR) and its association with clinicopathological outcomes in a large, multicenter cohort of patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP).

Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer

Study Type – Diagnosis (case series)
Level of Evidence 4

OBJECTIVE

To test whether the number or percentage of positive biopsy cores can be used to discriminate between patients with prostate cancer of a favourable and less favourable Gleason score (GS) ≤3 + 3, as prognostically, not all GS 3 + 3 prostate cancers are the same.

PATIENTS AND METHODS

In all, 1106 consecutive patients with a prostate‐specific antigen (PSA) level of ≤10 ng/mL and a biopsy GS of ≤3 + 3 or 3 + 4 had an open radical prostatectomy. The number of positive biopsy cores (≤2 vs ≥3) were stratified into low‐ vs high‐risk groups. Subsequently, we stratified patients according to the GS and the percentage of positive biopsy cores (<50% vs ≥50%). The pathological stage and the 5‐year biochemical recurrence (BCR)‐free survival rates were examined in univariable and multivariable models.

RESULTS

Based on the number of positive cores, the rate of extraprostatic disease was 11.7% and 23.3%, respectively, in the low‐and high‐risk GS ≤3 + 3 groups (P < 0.001). The 5‐year BCR‐free survival rates were 95.0%, 77.8%, 81.2% and 66.5% for, respectively, low‐ and high‐risk GS ≤3 + 3 and for low‐ and high‐risk GS 3 + 4 patients. Univariable and multivariable intergroup BCR rate differences were statistically significant between low‐ vs high‐risk GS 3 + 3 patients (P < 0.001), but not significant between high‐risk GS ≤3 + 3 vs low‐risk GS 3 + 4 patients (P = 0.6). Comparable results were obtained when comparisons were made according to the percentage of positive biopsy cores.

CONCLUSIONS

Our results corroborate the finding that not all patients with a biopsy GS of ≤3 + 3 prostate cancer have low‐risk disease. High‐risk GS ≤3 + 3 patients have a similar risk profile as more favourable GS 3 + 4 patients. This finding warrants consideration when deciding on treatment.     

TSP-1在前列腺癌中的表达及临床意义

目的:探讨前列腺癌中肿瘤血管生成与凝血酶敏感蛋白-1(TSP-1)表达的相关性。方法:采用免疫组织化学方法检测22例前列腺癌中微血管密度(MVD)值和TSP-1的表达,采用RT-PCR检测7例前列腺癌组织中TSP-1mRNA的表达。结果:前列腺癌中TSP-1阳性表达率为72.7%(16/22),绝大多数表达位于肿瘤细胞的胞质中,少数表达位于肿瘤细胞外基质。在22例前列腺癌组织中,平均MVD为71.21±31.14/100倍视野,具有TSP-1强表达的肿瘤组织中MVD值较高。7例前列腺癌组织均表达TSP-1mRNA,TSP-1mRNA在前列腺癌的各期肿瘤组织呈高水平表达。TSP-1的免疫活性与微血管密度间呈显著地相关性(r=0.54,P=0.009)。结论:TSP-1在前列腺癌组织中呈高表达,与前列腺癌的血管生成相关,可能有促进前列腺癌血管生长的作用。     

Correlation of serum PSA and Gleason score in Nigerian men with prostate cancer

Objective  Prostate cancer is an important cause of morbidity and mortality worldwide. While the predisposing factors are not fully understood, African descent is an important risk factor, and prostate cancer has become the number-one cancer in Nigerian men. This was a retrospective study of the correlation between serum prostate specific antigen (PSA) and Gleason grade and score in patients of Nigerian descent. Patients and Methods  The University College Hospital (UCH) Ibadan Cancer Registry was used to identify and quantify the incidence of prostate cancers occurring between 1998 and 2000. The histological slides of appropriate cases were reviewed to confirm the Gleason grade and score. The serum PSA values were retrieved from the patients' case notes and laboratory files. The data obtained were subjected to statistical analysis to look for associations and correlations. Results  The study included 67 men with prostate adenocarcinoma and PSA measurements who were diagnosed and treated at the UCH Ibadan between January 1998 and December 2000. There was a positive correlation between serum PSA and Gleason grade, as well as between serum PSA and Gleason score in our cohort of Nigerian African men with prostate cancer. PSA levels were significantly lower in patients with stage B disease than in patients with stage D disease. Conclusion  Serum PSA is significantly higher in metastatic than in localized disease. Further studies are necessary to determine biomarkers that complement serum PSA and the Gleason grading system in the prognostication of prostate cancer in African patients.     

Survival outcomes in prostate cancer patients with a prior cancer

BackgroundTo shed light on the survival outcomes of prostate cancer (PCa) patients diagnosed after a prior cancer and identify prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in PCa patients.MethodsIn the primary group, a total of 1,778 PCa patients with a prior cancer were identified in the Surveillance, Epidemiology, and End Results (SEER) database from 2005 to 2015, retrospectively. Baseline characteristics and causes of death (COD) of these patients were collected and compared. In the second group, a total of 10,296 PCa patients [5,148 patients with PCa as the only malignancy and 5,148 patients with PCa as their second primary malignancy (SPM)] diagnosed between 2010 and 2011 were extracted to investigate the impact of prior cancers on survival outcomes.ResultsIn PCa patients with a prior cancer, the most common type of prior cancer was from gastrointestinal system (29.92%), followed by urinary system (21.37%). Patients were more likely to die of the prior caner, and those with prior cancer from respiratory system had the worst survival outcomes. Moreover, the overall ratios in patients with stage (PCa) I–II and III–IV diseases were 0.21 and 1.65, indicating that patients with higher stage diseases were more likely to die of PCa. In the second group, patients with PCa as the SPM had worse OS than those with PCa as the first primary cancer. Lastly, prognostic factors for OS and CSS in PCa patients were explored.ConclusionsPCa remains to be an important COD for patients with a prior malignancy, especially for those with high-stage diseases. PCa patients with a prior cancer had worse survival outcomes than those without.